ATE420071T1 - 2- (1h-indolylsulfanyl) -arylaminderivate zur verwendung bei der behandlung von affektiven psychosen, schmerzen, dem hyperkinetischen syndrom des kindesalters (adhd) und stressharninkontinenz - Google Patents

2- (1h-indolylsulfanyl) -arylaminderivate zur verwendung bei der behandlung von affektiven psychosen, schmerzen, dem hyperkinetischen syndrom des kindesalters (adhd) und stressharninkontinenz

Info

Publication number
ATE420071T1
ATE420071T1 AT05759183T AT05759183T ATE420071T1 AT E420071 T1 ATE420071 T1 AT E420071T1 AT 05759183 T AT05759183 T AT 05759183T AT 05759183 T AT05759183 T AT 05759183T AT E420071 T1 ATE420071 T1 AT E420071T1
Authority
AT
Austria
Prior art keywords
indolylsulfanyl
adhd
children
pain
treatment
Prior art date
Application number
AT05759183T
Other languages
English (en)
Inventor
Jan Kehler
Friedrich Kroll
Karsten Juhl
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE420071T1 publication Critical patent/ATE420071T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT05759183T 2004-07-16 2005-07-13 2- (1h-indolylsulfanyl) -arylaminderivate zur verwendung bei der behandlung von affektiven psychosen, schmerzen, dem hyperkinetischen syndrom des kindesalters (adhd) und stressharninkontinenz ATE420071T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58855504P 2004-07-16 2004-07-16
DKPA200401121 2004-07-16
US69173605P 2005-06-17 2005-06-17
DKPA200500893 2005-06-17

Publications (1)

Publication Number Publication Date
ATE420071T1 true ATE420071T1 (de) 2009-01-15

Family

ID=39243745

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05759183T ATE420071T1 (de) 2004-07-16 2005-07-13 2- (1h-indolylsulfanyl) -arylaminderivate zur verwendung bei der behandlung von affektiven psychosen, schmerzen, dem hyperkinetischen syndrom des kindesalters (adhd) und stressharninkontinenz

Country Status (26)

Country Link
US (1) US7678800B2 (de)
EP (1) EP1771415B1 (de)
JP (1) JP4865710B2 (de)
KR (1) KR20070036061A (de)
CN (1) CN1972911A (de)
AR (1) AR052308A1 (de)
AT (1) ATE420071T1 (de)
AU (1) AU2005263324A1 (de)
BR (1) BRPI0512073A (de)
CA (1) CA2570805C (de)
CY (1) CY1108942T1 (de)
DE (1) DE602005012272D1 (de)
DK (1) DK1771415T3 (de)
EA (1) EA011418B1 (de)
ES (1) ES2317266T3 (de)
HR (1) HRP20090112T3 (de)
IL (1) IL179924A0 (de)
MX (1) MXPA06015201A (de)
NO (1) NO20066010L (de)
PL (1) PL1771415T3 (de)
PT (1) PT1771415E (de)
RS (1) RS50804B (de)
SI (1) SI1771415T1 (de)
UA (1) UA82610C2 (de)
WO (1) WO2006007843A1 (de)
ZA (1) ZA200610162B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
EP2297070A2 (de) * 2008-07-03 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Verbindungen und verfahren zur herstellung von radiopharmazeutika
RU2015145162A (ru) * 2013-11-14 2017-12-19 Кэлифорниа Инститьют Оф Текнолоджи Аккомодирующая интраокулярная линза
EP3083588B1 (de) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatische heterocyclische verbindungen und deren anwendung in pharmazeutika
US9974785B2 (en) 2014-07-08 2018-05-22 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
CN108536644B (zh) * 2015-12-04 2022-04-12 格兰菲智能科技有限公司 由装置端推核心入队列的装置

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803143A (en) 1969-09-08 1974-04-09 Eisai Co Ltd 6-amino alkylene 6,7-dihydro-5h-dibenzo (b,g),(1,5)thiazocines
US4018830A (en) 1969-09-22 1977-04-19 Merck & Co., Inc. Phenylthioaralkylamines
US4055665A (en) 1974-11-25 1977-10-25 Merck & Co., Inc. Treating arrythmia with phenylthioaralkylamines
US4056632A (en) 1975-07-21 1977-11-01 Burroughs Wellcome Co. 2-Hydroxymethyl-2'-aminomethyl-diphenylsulfides and method of use
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
EP0396827A1 (de) 1989-05-09 1990-11-14 SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu 2-Phenylthiobenzylamin-Derivate und Säureadditionssalze davon
GB8912971D0 (en) 1989-06-06 1989-07-26 Wellcome Found Halogen substituted diphenylsulfides
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
HUT69705A (en) 1991-11-25 1995-09-28 Pfizer Indole derivatives
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
ES2239766T3 (es) 1995-01-23 2005-10-01 Daiichi Suntory Pharma Co., Ltd. Alivio o remedio para sintomas causados por enfermedades isquemicas y compuestos de fenilpiperidina utilizados para ello.
ES2128281T1 (es) 1995-11-06 1999-05-16 Gist Brocades Bv Proceso de desesterificacion.
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
EP0923548B1 (de) 1996-08-27 2003-03-12 Wyeth 4-aminoethoxy-indolderivate als dopamin d2 agonisten und als 5ht1a liganden
GB9725953D0 (en) 1997-12-08 1998-02-04 Pfizer Ltd Compounds useful in therapy
DE19756036A1 (de) 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
US6333146B1 (en) 1999-03-10 2001-12-25 Fuji Photo Film Co., Ltd. Methine compound and silver halide photographic material containing the same
IL145528A0 (en) 1999-04-02 2002-06-30 Icos Corp INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF
CA2372481A1 (en) 1999-04-30 2000-11-09 The Trustees Of The University Of Pennsylvania Spect imaging agents for serotonin transporters
BR0012984A (pt) 1999-08-04 2002-07-16 Millennium Pharm Inc Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica
US6410736B1 (en) 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
TR200201004T2 (tr) 1999-10-13 2002-11-21 Pfizer Products Inc. Monoamin reuptake önleyicileri olarak biaril eter türevleri
IL150337A0 (en) 1999-12-30 2002-12-01 Lundbeck & Co As H Phenylpiperazinyl derivatives
UA72948C2 (uk) 1999-12-30 2005-05-16 Х. Луннбек А/С Заміщені похідні фенілпіперазину, фармацевтична композиція та спосіб лікування афективних або неврологічних захворювань і розладів
UA73756C2 (en) 1999-12-30 2005-09-15 Lundbeck & Co As H HALOGEN-SUBSTITUTED 4-PHENYL-1-PIPERAZIN, PIPERIDIN AND TETRAHYDROPIRIDINE û DERIVATIVES A PHARMACEUTICAL COMPOSITION BASED THEREON, THEIR APPLICATION FOR PRODUCING MEDICAMENT, AND A METHOD FOR THE TREATMENT OF PSYCHOSIS
AU2001243334A1 (en) 2000-02-29 2001-09-12 Integriderm, Inc. Inhibitors of melanocyte tyrosinase as topical skin lighteners
AU2001258771A1 (en) 2000-05-19 2001-11-26 Takeda Chemical Industries Ltd. -secretase inhibitors
US6455738B1 (en) 2000-07-13 2002-09-24 Rhodia Chimie Process for the sulfonation of an aromatic compound
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
AU2001279955A1 (en) 2000-08-18 2002-03-04 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
CZ2003493A3 (cs) 2000-09-01 2003-08-13 Fmc Corporation Disubstituované benzeny jakožto insekticidy
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
EP1193268A1 (de) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmazeutisch aktive Sulfonamidderivate mit sowohl lipophilen als auch ionisierbaren Gruppen als Inhibitoren von Protein-JunKinasen
US6852816B2 (en) 2000-10-06 2005-02-08 Biocompatibles Uk Limited Zwitterionic polymers
CA2425259A1 (en) 2000-10-11 2002-04-18 Tularik, Inc. Modulation of ccr4 function
WO2002040024A1 (en) 2000-11-14 2002-05-23 Merck Patent Gmbh Novel uses of combined 5-ht1a agonists and serotonin reuptake inhibitors
AR035521A1 (es) * 2000-12-22 2004-06-02 Lundbeck & Co As H Derivados de 3-indolina y composicion farmaceutica que los comprende
US6436938B1 (en) 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
CA2449874C (en) * 2001-06-07 2009-06-23 F. Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7064139B2 (en) 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
MXPA04004674A (es) 2001-11-14 2004-08-12 Schering Corp Ligados de los receptors de los canabinodies.
HUP0402319A2 (hu) 2001-12-21 2005-02-28 H. Lundbeck A/S Szerotonin és norepinefrin felvételt gátló aminoindán-származékok
US8048408B2 (en) 2002-01-16 2011-11-01 Biocompatibles Uk Limited Polymer conjugates
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
RU2314314C2 (ru) 2002-03-04 2008-01-10 Джапан Сайенс Энд Текнолоджи Эйдженси Новые фосфонамиды, способ их получения и их применение
AU2003218452C1 (en) 2002-03-29 2009-07-23 Massachusetts Institute Of Technology Light emitting device including semiconductor nanocrystals
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
US7217732B2 (en) 2002-06-19 2007-05-15 Schering Corporation Cannabinoid receptor agonists
TW200401641A (en) 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
KR100686758B1 (ko) 2002-09-17 2007-02-26 에프. 호프만-라 로슈 아게 2,7-치환된 인돌 및 5-ｈｔ6 조절 인자로서의 그 용도
MXPA05002836A (es) 2002-09-17 2005-05-27 Hoffmann La Roche Indoles 2,4-sustituidos y su uso como moduladores 5-ht6.
EP1402888A1 (de) 2002-09-18 2004-03-31 Jerini AG Verwendung von substituierte carbozyclische Verbindungen als rotamase inhibitoren
US20040266732A1 (en) 2002-09-20 2004-12-30 Jorge Galvez Therapeutic agents, methods, and treatments
MXPA05004128A (es) * 2002-10-18 2005-06-22 Hoffmann La Roche 4-piperazinil bencenosulfonil indoles con afinidad al receptor 5-hidroxitriptamina 6 (5-ht6).
US20040137389A1 (en) 2002-12-19 2004-07-15 Kouta Fukui Heat-developable light-sensitive material
CA2511214C (en) 2002-12-20 2012-12-18 Tularik, Inc. Asthma and allergic inflammation modulators
US7189501B2 (en) 2002-12-27 2007-03-13 Fuji Photo Film Co., Ltd. Silver halide color photographic photosensitive material
DE10300098A1 (de) 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
WO2004069888A2 (en) 2003-02-05 2004-08-19 Biocompatibles Uk Limited Block copolymers
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
WO2005035516A1 (ja) 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. 新規縮合複素環化合物およびその用途
US7229751B2 (en) 2003-11-20 2007-06-12 Konica Minolta Medical & Graphic, Inc. Silver salt photothermographic dry imaging material and image forming method using the same
CA2550091A1 (en) 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
BRPI0417858B1 (pt) 2003-12-23 2017-10-10 H. Lundbeck A/S Derivative compounds of aniline and pharmaceutical composition that understand it
SE528250C2 (sv) 2004-02-27 2006-10-03 Calignum Technologies Ab Komposition innefattande en initiator och ett förfarande för att behandla trä med kompositionen
JP4569142B2 (ja) 2004-03-22 2010-10-27 コニカミノルタホールディングス株式会社 表示素子
JP4448730B2 (ja) 2004-04-20 2010-04-14 富士フイルム株式会社 感光性組成物、該感光性組成物に用いられる化合物及び該感光性組成物を用いたパターン形成方法
WO2006006172A2 (en) 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006098380A1 (ja) 2005-03-15 2006-09-21 Fujifilm Corporation 円盤状化合物を用いた表面処理法、表面処理用（潤滑）組成物及び表面処理された物品

Also Published As

Publication number Publication date
RS50804B (sr) 2010-08-31
AU2005263324A1 (en) 2006-01-26
DK1771415T3 (da) 2009-02-23
ES2317266T3 (es) 2009-04-16
JP2008506640A (ja) 2008-03-06
CN1972911A (zh) 2007-05-30
BRPI0512073A (pt) 2008-02-06
CA2570805A1 (en) 2006-01-26
CY1108942T1 (el) 2014-07-02
KR20070036061A (ko) 2007-04-02
EA011418B1 (ru) 2009-02-27
DE602005012272D1 (de) 2009-02-26
AR052308A1 (es) 2007-03-14
US7678800B2 (en) 2010-03-16
PT1771415E (pt) 2009-03-16
ZA200610162B (en) 2008-06-25
MXPA06015201A (es) 2007-03-15
SI1771415T1 (sl) 2009-04-30
EA200602180A1 (ru) 2007-04-27
JP4865710B2 (ja) 2012-02-01
HRP20090112T3 (en) 2009-03-31
IL179924A0 (en) 2007-05-15
NO20066010L (no) 2006-12-27
US20080027074A1 (en) 2008-01-31
EP1771415A1 (de) 2007-04-11
EP1771415B1 (de) 2009-01-07
PL1771415T3 (pl) 2009-06-30
UA82610C2 (uk) 2008-04-25
CA2570805C (en) 2010-08-24
WO2006007843A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
ATE420071T1 (de) 2- (1h-indolylsulfanyl) -arylaminderivate zur verwendung bei der behandlung von affektiven psychosen, schmerzen, dem hyperkinetischen syndrom des kindesalters (adhd) und stressharninkontinenz
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE518841T1 (de) Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas
ATE447570T1 (de) Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen
DE502005003904D1 (de) Tetrahydrobenzo (d) azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
DE502005007427D1 (de) 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten
DE602004010419D1 (de) Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE602005015451D1 (de) Auf probiotischen bakterien basierende zusammensetzung und ihre verwendung zur vorbeugung und/oder behandlung von atemwegserkrankungen und/oder infektionen sowie zur verbesserung der darmtätigkeit
IS8134A (is) Píperasínafleiður og notkun þeirra til að meðhöndla tauga- og geðsjúkdóma
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
ATE495179T1 (de) Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE602005010222D1 (de) Verwendung eines phenothiazin-derivats zur prävention und/oder behandlung von gerhörverlust
ATE479716T1 (de) Copolymerisate und ihre verwendung zur behandlung von flexiblen substraten
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE362923T1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATE408602T1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE602005022175D1 (de) Prävention, behandlung und linderung strahlungsinduzierter enteritis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1771415

Country of ref document: EP